 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today announced that the European Commission has approved the use of Biofronteras prescription drug Ameluz in combination with photodynamic therapy PDT for the treatment of actinic keratosis AK on the extremities and trunkneck. With a recurrence rate of 19.5, Ameluz showed lower recurrence rates after 12 months than Metvix with 31.2. 